Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adjuvant chemo emerges as new standard in upper tract urothelial cancer

Publish date:: March 9, 2020

Key clinical point: Adjuvant chemotherapy improves outcomes in patients with locally advanced upper tract urothelial cancer.

Major finding: Compared with surveillance, platinum-based chemotherapy started within 90 days after nephroureterectomy sharply reduced the risk of disease-free survival events (hazard ratio, 0.45; P = .0001).

Study details: A phase 3, randomized trial of 261 patients with locally advanced upper tract urothelial cancer.

Disclosures: The trial was funded by Cancer Research UK. The authors disclosed relationships with numerous pharmaceutical companies.

Citation:

Birtle A et al. Lancet. 2020 Mar 5. doi: 10.1016/S0140-6736(20)30415-3.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,